Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-4a0e2349adfb2620b1fba9cd50d81a0a"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-4a0e2349adfb2620b1fba9cd50d81a0a"/>
<resource>
<Composition>
<id value="composition-en-4a0e2349adfb2620b1fba9cd50d81a0a"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-4a0e2349adfb2620b1fba9cd50d81a0a"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-4a0e2349adfb2620b1fba9cd50d81a0a</b></p><a name="composition-en-4a0e2349adfb2620b1fba9cd50d81a0a"> </a><a name="hccomposition-en-4a0e2349adfb2620b1fba9cd50d81a0a"> </a><a name="composition-en-4a0e2349adfb2620b1fba9cd50d81a0a-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/21/1552/001 10 mg hard capsules</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - koselugo</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/21/1552/001 10 mg hard capsules"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mp4a0e2349adfb2620b1fba9cd50d81a0a"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - koselugo"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet</p><ol type="1"><li>What Koselugo is and what it is used for</li><li>What you need to know before you take Koselugo</li><li>How to take Koselugo</li><li>Possible side effects</li><li>How to store Koselugo</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What koselugo is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What koselugo is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What Koselugo is and how it works Koselugo contains the active substance selumetinib. Selumetinib is a type of medicine called a MEK inhibitor. It works by blocking certain proteins involved in the growth of tumour cells. Koselugo is expected to shrink tumours that grow along nerves, called plexiform neurofibromas. These tumours are caused by a genetic condition called neurofibromatosis type 1 (NF1). What Koselugo is used for Koselugo is used to treat children aged 3 years and above with plexiform neurofibromas that cannot be completely removed by surgery. If you have any questions about how Koselugo works or why this medicine has been prescribed for you, ask your doctor.</p></div>
</text>
</section>
<section>
<title value="2. What you need to know before you take koselugo"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text
value="2. What you need to know before you take koselugo"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Do not take Koselugo:</p><p>if you are allergic to selumetinib or any of the other ingredients of this medicine (listed in section 6)</p><p>if you have severe liver disease If you are not sure, talk to your doctor, pharmacist or nurse before taking Koselugo. Warnings and precautions Talk to your doctor, pharmacist or nurse before and during your treatment with Koselugo:</p><p>if you have eye problems</p><p>if you have heart problems</p><p>if you have liver problems</p><p>if you take supplements containing vitamin E</p><p>if you cannot swallow the capsule whole If any of the above apply to you (or you are not sure) talk to your doctor, pharmacist or nurse before taking this medicine. Eye problems Koselugo can cause eye problems (see section 4 Possible side effects ). Tell your doctor straight away if you get blurred vision or any other changes to your sight during treatment. Your doctor should examine your eyes if you have any new or worsening problems with your sight while you are taking this medicine. Heart problems Koselugo can lower the amount of blood pumped by your heart (see section 4 Possible side-effects ). Your doctor will check how well your heart works before and during your treatment with Koselugo. Liver problems Koselugo can increase the amount of some liver enzymes in your blood (see section 4 Possible side effects ). Your doctor will do blood tests before and during treatment to check how well your liver is working. Supplemental vitamin E Koselugo capsules contain vitamin E that may increase your risk of bleeding. This means you should tell your doctor if you take other medicines that increase your risk of bleeding such as:</p><p>acetylsalicylic acid (also known as aspirin) for pain and inflammation</p><p>anticoagulant medicines (blood thinners) such as warfarin or other medicines used for preventing blood clots</p><p>supplements that may increase your risk of bleeding, such as vitamin E Difficulty swallowing capsules Talk to your doctor if you think you might have difficulties swallowing the capsules whole (see section 3 How to take Koselugo ).<br/>Skin, nail and hair problems Koselugo can cause skin rash, nail infection or hair thinning or changes in hair colour (see section 4 Possible side effects ). Tell your doctor if any of these symptoms trouble you during treatment. Children under 3 years old Do not give Koselugo to children below 3 years of age. This is because it has not been studied in this age group. Other medicines and Koselugo Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. This includes herbal medicines, supplements and medicines obtained without a prescription. Koselugo can affect the way some other medicines work. Also, some other medicines can affect the way Koselugo works. Tell your doctor if you are taking any of the following medicines:</p><p>clarithromycin or erythromycin (used to treat bacterial infections)</p><p>carbamazepine or phenytoin (used to treat seizures and epilepsy)</p><p>digoxin (used to treat heart failure)</p><p>fexofenadine (used to treat symptoms of allergy)</p><p>fluconazole or itraconazole (used to treat fungal infections)</p><p>ketoconazole (used to treat Cushing s syndrome)</p><p>furosemide (used to treat fluid retention by increasing the amount of urine you pass)</p><p>methotrexate (used to treat some types of cancer, psoriasis or rheumatoid arthritis)</p><p>omeprazole (used to treat acid reflux or stomach ulcer)</p><p>rifampicin (used to treat tuberculosis (TB) and some other bacterial infections)</p><p>St. John s wort (Hypericum perforatum), a herbal medicine (used to treat mild depression and other conditions)</p><p>ticlopidine (used to prevent blood clots) Tell your doctor or pharmacist if you are taking or have recently taken any of the above or any other medicines, even those that are not prescribed. Koselugo with food and drink Do not drink grapefruit juice while you are taking Koselugo because, it can affect the way the medicine works. Pregnancy information for women Koselugo is not recommended during pregnancy. It may cause harm to an unborn baby. If you think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. Your doctor may ask you to take a pregnancy test before starting treatment. You should not become pregnant while taking this medicine. If you are able to become pregnant, you must use effective contraception. See Contraception - information for women and men below. If you become pregnant during treatment, tell your doctor straight away. Pregnancy information for men If your partner becomes pregnant while you are taking this medicine, tell your doctor straight away. Contraception information for women and men If you are sexually active you should use effective contraception while you are taking this medicine and for at least 1 week after the last dose. It is not known whether Koselugo may interfere with how well hormonal contraceptives work. Please tell your doctor if you are taking a hormonal contraceptive, as your doctor may recommend the addition of a non-hormonal method of birth control. Breast-feeding Do not breast-feed if you are taking Koselugo. It is not known if Koselugo passes into breast milk. Driving and using machines Koselugo can cause side effects that affect your ability to drive or use machines. Do not drive or use machines if you feel tired or if you have problems with your vision (such as blurred vision).</p></div>
</text>
</section>
<section>
<title value="3. How to take koselugo"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take koselugo"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. How much to take Your doctor will work out the correct dose for you based on your height and weight. The doctor will tell you how many capsules of Koselugo to take. Your doctor may prescribe a lower dose if you have problems with your liver (hepatic impairment). Your doctor may reduce your dose if you have certain side effects while you are taking Koselugo (see section 4 Possible side effects ) or the doctor may interrupt treatment or stop it permanently. How to take</p><p>Take Koselugo twice a day, about 12 hours apart, with or without food.</p><p>Swallow the capsules whole with water.</p><p>Do not chew, dissolve, or open the capsules.</p><p>If you have, or think you might have difficulty swallowing capsules whole, talk to your doctor before starting treatment.<br/>If you are sick If you are sick (vomit) at any time after taking Koselugo, do not take an extra dose. Take the next dose at the normal time. If you take more Koselugo than you should If you have taken more Koselugo than you should, contact your doctor or pharmacist immediately. If you forget to take Koselugo What to do if you forget to take a dose of Koselugo depends on how long it is until your next dose.</p><p>If it is more than 6 hours until your next dose, take the missed dose. Then take the next dose at the normal time.</p><p>If it is less than 6 hours until your next dose, skip the missed dose. Then take the next dose at the normal time. Do not take a double dose (two doses at the same time) to make up for a forgotten dose. If you stop taking Koselugo Do not stop taking Koselugo unless your doctor tells you. If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Possible serious side effects Eye (vision) problems Koselugo can cause eye problems. Tell your doctor straight away if you get blurred vision (a very common side effect that may affect more than 1 in 10 people) or any other changes to your sight during treatment. Your doctor may ask you to stop taking this medicine or send you to a specialist, if you develop symptoms that include:</p><p>blurred vision</p><p>loss of vision</p><p>dark spots in your vision (floaters)</p><p>other changes to your vision (such as reduced vision) Tell your doctor straight away if you notice any of the serious side effects above. Other side effects Tell your doctor or pharmacist if you notice any of the following side effects: Very common (may affect more than 1 in 10 people)</p><p>being sick (vomiting), feeling sick (nausea)</p><p>diarrhoea</p><p>inflammation of the mouth (stomatitis)</p><p>skin and nail problems - signs may include dry skin, rash, redness around the fingernails</p><p>hair thinning (alopecia), hair colour change</p><p>feeling tired, weak or lacking energy</p><p>fever (pyrexia)</p><p>swelling of the hands or feet (peripheral oedema)</p><p>a slight decrease in the amount of blood that the heart is pumping (ejection fraction decreased)<br/>signs may include shortness of breath or swelling in your legs, ankles or feet</p><p>high blood pressure (hypertension)</p><p>reduced level of albumin, an essential protein in the blood (shown in blood tests)</p><p>reduced haemoglobin, the oxygen-carrying protein in red blood cells (shown in blood tests)</p><p>increase in enzymes (shown in blood tests) suggesting stress on the liver, kidney injury or muscle breakdown Common (may affect up to 1 in 10 people)</p><p>dry mouth</p><p>swelling of the face (facial oedema)</p><p>shortness of breath (dyspnoea) Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>
</text>
</section>
<section>
<title value="5. How to store koselugo"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store koselugo"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the bottle and carton after EXP. The expiry date refers to the last day of that month. Do not store above 30 C. Store in the original bottle in order to protect from moisture and light. Keep the bottle tightly closed. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What Koselugo contains The active substance is selumetinib. Each Koselugo 10 mg hard capsule contains 10 mg of selumetinib (as hydrogen sulfate). Each Koselugo 25 mg hard capsule contains 25 mg of selumetinib (as hydrogen sulfate). The other ingredients in Koselugo 10 mg hard capsules are:</p><p>capsule fill: vitamin E polyethylene glycol succinate (D -tocopheryl polyethylene glycol succinate).</p><p>capsule shell: hypromellose (E464), carrageenan (E407), potassium chloride (E508), titanium dioxide (E171), carnauba wax (E903).</p><p>printing ink: shellac standard (E904), iron oxide black (E172), propylene glycol (E1520) ammonium hydroxide (E527). The other ingredients in Koselugo 25 mg hard capsules are:</p><p>capsule fill: vitamin E polyethylene glycol succinate (D -tocopheryl polyethylene glycol succinate).</p><p>capsule shell: hypromellose (E464), carrageenan (E407), potassium chloride (E508), titanium dioxide (E171), indigo carmine aluminium lake (E132), iron oxide yellow (E172), carnauba wax (E903), maize starch.</p><p>printing ink: iron oxide red (E172), iron oxide yellow (E172), indigo carmine aluminium lake (E132), carnauba wax (E903), shellac, standard (E904), glyceryl mono-oleate. What Koselugo looks like and contents of the pack Koselugo 10 mg hard capsule is a white to off-white, opaque, hard capsule which has a centre band and is marked with SEL 10 in black ink. Koselugo 25 mg hard capsule is a blue, opaque, hard capsule which has a centre band and is marked with SEL 25 in black ink. Koselugo is provided in white plastic bottles, capped with a white (10 mg) or blue (25 mg) child- resistant closure containing 60 hard capsules and a silica gel desiccant. Do not remove the desiccant from the bottle and do not swallow it. Marketing Authorisation Holder AstraZeneca AB SE-151 85 S dert lje Sweden Manufacturer AstraZeneca AB Karlebyhusentr n Astraall n SE-152 57 S dert lje Sweden For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder: Belgi /Belgique/Belgien Alexion Pharma Belgium Tel: +32 800 200 Lietuva UAB AstraZeneca Lietuva Tel: +370 5 2660</p><p>.: +359 24455Luxembourg/Luxemburg Alexion Pharma Belgium T l/Tel: +32 800 200 esk republika AstraZeneca Czech Republic s.r.o. Tel: +420 222 807 Magyarorsz g AstraZeneca Kft. Tel.: +36 1 883 6Danmark AstraZeneca A/S Tlf: +45 43 66 64 Malta Associated Drug Co. Ltd Tel: +356 2277 8Deutschland AstraZeneca GmbH Tel: +49 40 809034Nederland AstraZeneca BV Tel: +31 85 808 9Eesti AstraZeneca Tel: +372 6549 Norge AstraZeneca AS Tlf: +47 21 00 64<br/>AstraZeneca A.E. : +30 210 6871 sterreich AstraZeneca sterreich GmbH Tel: +43 1 711 31 0 Espa a Alexion Pharma Spain, S.L. Tel: +34 93 272 30 Polska AstraZeneca Pharma Poland Sp. z o.o. Tel.: +48 22 245 73 France Alexion Pharma France SAS T l: +33 1 47 32 36 Portugal Alexion Pharma Spain, S.L. - Sucursal em Portugal Tel: +34 93 272 30 Hrvatska AstraZeneca d.o.o. Tel: +385 1 4628 Rom nia AstraZeneca Pharma SRL Tel: +40 21 317 60 Ireland AstraZeneca Pharmaceuticals (Ireland) DAC Tel: +353 1609 7Slovenija AstraZeneca UK Limited Tel: +386 1 51 35 sland Vistor hf. S mi: +354 535 7Slovensk republika AstraZeneca AB, o.z. Tel: +421 2 5737 7Italia Alexion Pharma Italy srl Tel: +39 02 7767 9Suomi/Finland AstraZeneca Oy Puh/Tel: +358 10 23</p><p>: +357 22490Sverige AstraZeneca AB Tel: +46 8 553 26 Latvija SIA AstraZeneca Latvija Tel: +371 67377United Kingdom (Northern Ireland) AstraZeneca UK Ltd Tel: +44 1582 836 This leaflet was last revised in This medicine has been given conditional approval . This means that there is more evidence to come about this medicine. The European Medicines Agency will review new information on this medicine at least every year and this leaflet will be updated as necessary. Other sources of information Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mp4a0e2349adfb2620b1fba9cd50d81a0a"/>
<resource>
<MedicinalProductDefinition>
<id value="mp4a0e2349adfb2620b1fba9cd50d81a0a"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mp4a0e2349adfb2620b1fba9cd50d81a0a"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mp4a0e2349adfb2620b1fba9cd50d81a0a</b></p><a name="mp4a0e2349adfb2620b1fba9cd50d81a0a"> </a><a name="hcmp4a0e2349adfb2620b1fba9cd50d81a0a"> </a><a name="mp4a0e2349adfb2620b1fba9cd50d81a0a-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/21/1552/001 10 mg hard capsules</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Koselugo 10 mg hard capsules</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/21/1552/001 10 mg hard capsules"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName value="Koselugo 10 mg hard capsules"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
